1Coates AS, Winer EP, Goldhir'h A, et al. Tailoring therapies- improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [ J]. Ann Oncol, 2015, 26 ( 8 ) : 1533-1546. DOI : 10. 1093/annonc/mdv221.
2Hammond ME, Hayes DF, Wolff AC, et al. American society of clinical oncology/college of american pathologists guideline recommendations for testing of estrogen and progesterone receptors in breast cancer[ J ]. J Oncol Pract,2010, 6 ( 4 ) : 195 -197. DOI: 10. 1200/JOP. 777003.
3Deyarmin B, Kane JL, Valente AL, et al. Effect of ASCO/CAP guidelines for determining ER status on molecular subtype [ J ]. Ann Surg Oneol, 2013, 20 ( 1 ) : 87-93. DOI: 10. 1245/s10434-012-2588.
4Yi M, Huo L, Koenig KB, et al. Which threshold for ER positivity? A retrospective study based on 9639 patients[J]. Ann Oncol, 2014, 25 ( 5 ) : 1004-1011. DOI: 10. 1093/annone/ mdu053.
5Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [ J ]. Ann Oncol, 2013, 24 (9) : 2206-2223. DOI : 10. 1093/annonc/mdt303.
6Li AQ, Zhou SL, Li M, et al. Clinieopathologie characteristics of oestrogen receptor-positive/progesterone receptor-negative/Her2- negative breast cancer according to a novel definition of negative progesterone receptor status: a large population-based study from China[J]. PLoS One, 2015, 10(5) : e0125067. DOI:10.1371/ journal, pone. 0125067.
7Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures [J]. Breast Cancer Res, 2008, 10(4): R65. DOI: 10. 1186/ ber2124.
8de Azambuja E, Cardoso F, de Castro G, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients [ J ]. Br J Cancer, 2007, 96 (10) : 1504-1513. DOI: 10. 1038/@ bjc. 6603756.
9Criscitiello C, Disalvatore D, De Laurentiis M, et al. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer [ J ]. Breast, 2014, 23 ( 1 ) : 69-75. DOI : 10. 1016/j. breast. 2013.11. 007.
10Polley MY, Leung SC, McShane LM, et al. An international Ki67 reproducibility study[ J ]. J Natl Cancer Inst, 2013, 105 ( 24 ) : 1897-1906. DOI: 10. 1093/jnci/djt306.
